Optimizing the Use of Renin‐Angiotensin System Inhibition in Advanced Chronic Kidney Disease
DOI:
https://doi.org/10.71749/pkj.58Keywords:
Angiotensin Receptor Antagonists/therapeutic use, Angiotensin‐Converting Enzyme Inhibitors/therapeutic use, Kidney Failure, Chronic/drug therapy, Renal Insufficiency, Chronic/drug therapyAbstract
Chronic kidney disease (CKD) affects millions of people worldwide and is a major public health problem. Renin‐angiotensin system inhibitors are the backbone drugs for preventing CKD progression but have potential side effects, such as hyperkalemia or acute decrease in glomerular filtration rate, which can prevent physicians from starting the drugs, or even lead physicians to stop the drug when already in use in advanced CKD patients. In this review, the princi‐ pal studies performed on this topic are summarized.Downloads
References
Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022;12(1):7-11. Epub 2022/05/10. doi: 10.1016/j.kisu.2021.11.003. PubMed PMID: 35529086; PubMed Central PMCID: PMCPMC9073222.
Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. The Lancet. 2018;392(10159):2052-90. doi: 10.1016/S0140-6736(18)31694-5.
Boerstra BA, Boenink R, Astley ME, Bonthuis M, Abd ElHafeez S, Arribas Monzón F, et al. The ERA Registry Annual Report 2021: a summary. Clin Kidney J. 2024;17(2):sfad281. Epub 2024/04/19. doi: 10.1093/ckj/sfad281. PubMed PMID: 38638342; PubMed Central PMCID: PMCPMC11024806.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4s):S117-s314. Epub 2024/03/16. doi: 10.1016/j.kint.2023.10.018. PubMed PMID: 38490803.
Cohen JB, Hanff TC, Bress AP, South AM. Relationship Between ACE2 and Other Components of the Renin-Angiotensin System. Curr Hypertens Rep. 2020;22(7):44. Epub 2020/06/28. doi: 10.1007/s11906-020-01048-y. PubMed PMID: 32591908; PubMed Central PMCID: PMCPMC7317893.
Tonneijck L, Muskiet MH, Smits MM, van Bommel EJ, Heerspink HJ, van Raalte DH, et al. Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment. J Am Soc Nephrol. 2017;28(4):1023-39. Epub 2017/02/02. doi: 10.1681/asn.2016060666. PubMed PMID: 28143897; PubMed Central PMCID: PMCPMC5373460.
Clase CM, Carrero JJ, Ellison DH, Grams ME, Hemmelgarn BR, Jardine MJ, et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2020;97(1):42-61. Epub 2019/11/11. doi: 10.1016/j.kint.2019.09.018. PubMed PMID: 31706619.
Chen TK, Sperati CJ, Thavarajah S, Grams ME. Reducing Kidney Function Decline in Patients With CKD: Core Curriculum 2021. Am J Kidney Dis. 2021;77(6):969-83. Epub 2021/04/25. doi: 10.1053/j.ajkd.2020.12.022. PubMed PMID: 33892998; PubMed Central PMCID: PMCPMC8227808.
de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2022;102(5):974-89. Epub 2022/10/07. doi: 10.1016/j.kint.2022.08.012. PubMed PMID: 36202661.
KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3s):S1-s87. Epub 2021/02/28. doi: 10.1016/j.kint.2020.11.003. PubMed PMID: 33637192.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329(20):1456-62. Epub 1993/11/11. doi: 10.1056/nejm199311113292004. PubMed PMID: 8413456.
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-9. Epub 2001/09/22. doi: 10.1056/NEJMoa011161. PubMed PMID: 11565518.
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes. New England Journal of Medicine. 2001;345(12):851-60. doi: doi:10.1056/NEJMoa011303.
Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy. New England Journal of Medicine. 2013;369(20):1892-903. doi: doi:10.1056/NEJMoa1303154.
Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. New England Journal of Medicine. 2008;358(15):1547-59. doi: doi:10.1056/NEJMoa0801317.
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The Lancet. 1997;349(9069):1857-63. doi: 10.1016/S0140-6736(96)11445-8.
Wright J, Jackson T., Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney DiseaseResults From the AASK Trial. JAMA. 2002;288(19):2421-31. doi: 10.1001/jama.288.19.2421.
Foti KE, Wang D, Chang AR, Selvin E, Sarnak MJ, Chang TI, et al. Potential implications of the 2021 KDIGO blood pressure guideline for adults with chronic kidney disease in the United States. Kidney Int. 2021;99(3):686-95. Epub 2021/02/28. doi: 10.1016/j.kint.2020.12.019. PubMed PMID: 33637204; PubMed Central PMCID: PMCPMC7958922.
Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006;354(2):131-40. Epub 2006/01/13. doi: 10.1056/NEJMoa053107. PubMed PMID: 16407508.
Fu EL, Clase CM, Evans M, Lindholm B, Rotmans JI, Dekker FW, et al. Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals With Advanced CKD: A Nationwide Observational Cohort Study. Am J Kidney Dis. 2021;77(5):719-29.e1. Epub 2020/11/28. doi: 10.1053/j.ajkd.2020.10.006. PubMed PMID: 33246024.
Ahmed AK, Kamath NS, El Kossi M, El Nahas AM. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant. 2010;25(12):3977-82. Epub 2009/10/13. doi: 10.1093/ndt/gfp511. PubMed PMID: 19820248.
Qiao Y, Shin JI, Chen TK, Inker LA, Coresh J, Alexander GC, et al. Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate. JAMA Intern Med. 2020;180(5):718-26. Epub 2020/03/10. doi: 10.1001/jamainternmed.2020.0193. PubMed PMID: 32150237; PubMed Central PMCID: PMCPMC7063544 outside the submitted work. Dr Chen reported receiving grants from Yale University and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and receiving grant support from a George M. O'Brien Center for Kidney Research Pilot and Feasibility Grant from Yale University and award K08DK117068 from the National Institutes of Health (NIH)/NIDDK. Dr Inker reported receiving grants from the NIH, National Kidney Foundation, Retrophin, Omeros, and Reata Pharmaceuticals and consulting for Tricida Inc. Dr Coresh reported receiving grants from the NIH and the National Kidney Foundation during the conduct of the study. Dr Alexander reported serving as a past chair of the US Food and Drug Administration’s Peripheral and Central Nervous System Advisory Committee, serving as a paid adviser to IQVIA, serving as a cofounding principal and equity holder in Monument Analytics, a health care consultancy whose clients include the life sciences industry as well as plaintiffs in opioid litigation, and serving as a member of OptumRx's National P&T Committee. This arrangement has been reviewed and approved by Johns Hopkins University in accordance with its conflict of interest policies. Dr Grams reported receiving grants from the NIDDK during the conduct of the study and travel support from Dialysis Clinics Inc outside the submitted work. No other disclosures were reported.
Walther CP, Winkelmayer WC, Richardson PA, Virani SS, Navaneethan SD. Renin-angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease. Nephrol Dial Transplant. 2021;36(10):1893-9. Epub 2020/12/29. doi: 10.1093/ndt/gfaa300. PubMed PMID: 33367872; PubMed Central PMCID: PMCPMC8633426.
Fu EL, Evans M, Clase CM, Tomlinson LA, van Diepen M, Dekker FW, et al. Stopping Renin-Angiotensin System Inhibitors in Patients with Advanced CKD and Risk of Adverse Outcomes: A Nationwide Study. J Am Soc Nephrol. 2021;32(2):424-35. Epub 2020/12/30. doi: 10.1681/asn.2020050682. PubMed PMID: 33372009; PubMed Central PMCID: PMCPMC8054897.
Bhandari S, Mehta S, Khwaja A, Cleland JGF, Ives N, Brettell E, et al. Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease. N Engl J Med. 2022;387(22):2021-32. Epub 2022/11/04. doi: 10.1056/NEJMoa2210639. PubMed PMID: 36326117.
Naveed H, Tirumandyam G, Krishna Mohan GV, Gul S, Ali S, Siddiqui A, et al. Effect of Discontinuation of Renin Angiotensin-System Inhibitors in Patients With Advanced Chronic Kidney Disease: A Meta-Analysis. Cureus. 2023;15(4):e37813. Epub 2023/05/22. doi: 10.7759/cureus.37813. PubMed PMID: 37214072; PubMed Central PMCID: PMCPMC10197020.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Ana Carina Ferreira (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
